Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 288

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 288
---
100.0  

Table of Contents

We cannot determine with certainty the duration and completion costs of the current or future pre-clinical or clinical studies of our drug candidates or if, when, or to what extent we will generate revenue from the commercialization and sale of any of our drug candidates that obtain regulatory approval. We may not succeed in achieving regulatory approval for any of our drug candidates currently under development. The duration, costs, and timing of clinical studies and development of our drug candidates will depend on a variety of factors, including:

  the scope, rate of progress and expense of our ongoing as well as any additional clinical studies and other research and development activities;  

  future clinical study results;  

  uncertainties in clinical study enrollment rate;  

  significant and changing government regulations; and  

  the timing and receipt of any regulatory approvals.  

A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate.

For more information on the risks associated with the development of our drug candidates, see Item 3. D. “ Risk Factors - Risks Relating to Our Oncology/Immunology Operations and Development of Our Drug Candidates - All of our drug candidates are still in development. If we are unable to obtain regulatory approval and ultimately commercialize our drug candidates, or if we experience significant delays in doing so, our business will be materially harmed.”

Selling Expenses

The following table sets forth the components of our selling expenses for the years indicated.

                           Year Ended December 31,                                                             
                                              2024                    2023                    2022             
                                           $ ’ 000          %      $ ’ 000          %      $ ’ 000          %  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Selling Expenses                                                                                             
  Oncology/Immunology                       44,287       91.1       45,505       85.2       33,862       77.1  
  Other Ventures                             4,330        8.9        7,887       14.8       10,071       22.9  
  Total                                     48,617      100.0       53,392      100.0       43,933      100.0  

Our selling expenses primarily comprise selling expenses incurred by our Oncology/Immunology operations by HUTCHMED